Dimension Therapeutics Report issue

For profit Phase 2
Founded: Cambridge MA United States (2013)
Status: Acquired by Ultragenyx Inc. (2017)

Organization Overview

First Clinical Trial
2015
NCT02618915
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dimension Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

aavrh10fix (1 trial)

scaav8otc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemophilia A (Phase 2)

Hemophilia B (Phase 2)

Ornithine Carbamoyltransferase Deficiency Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2